Latest & greatest articles for fluconazole

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on fluconazole or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on fluconazole and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for fluconazole

1. Itraconazole vs fluconazole for the treatment of uncomplicated acute vaginal and vulvovaginal candidiasis in nonpregnant women: a metaanalysis of randomized controlled trials

Itraconazole vs fluconazole for the treatment of uncomplicated acute vaginal and vulvovaginal candidiasis in nonpregnant women: a metaanalysis of randomized controlled trials Itraconazole vs fluconazole for the treatment of uncomplicated acute vaginal and vulvovaginal candidiasis in nonpregnant women: a metaanalysis of randomized controlled trials Itraconazole vs fluconazole for the treatment of uncomplicated acute vaginal and vulvovaginal candidiasis in nonpregnant women: a metaanalysis (...) of randomized controlled trials Pitsouni E, Iavazzo C, Falagas M E CRD summary This review assessed the effectiveness and safety of oral itraconazole and fluconazole for uncomplicated acute vaginal and vulvovaginal candidiasis in non pregnant women, concluding that both regimens had similar effectiveness and safety. The reliability of the conclusion was uncertain given the poor quality of the included studies. Authors' objectives To assess the effectiveness and safety of oral itraconazole and fluconazole

2008 DARE.

2. Cohort study: Oral fluconazole is often used during pregnancy in the treatment of vulvovaginal candidiasis despite safety concerns to the fetus

Cohort study: Oral fluconazole is often used during pregnancy in the treatment of vulvovaginal candidiasis despite safety concerns to the fetus Oral fluconazole is often used during pregnancy in the treatment of vulvovaginal candidiasis despite safety concerns to the fetus | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please (...) see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Oral fluconazole is often used during pregnancy in the treatment of vulvovaginal candidiasis despite safety concerns

2016 Evidence-Based Nursing

3. Yeast infection in pregnancy? Think twice about fluconazole

Yeast infection in pregnancy? Think twice about fluconazole Yeast infection in pregnancy? Think twice about fluconazole Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Yeast infection in pregnancy? Think twice about fluconazole View/ Open Date 2016-09 Format Metadata Abstract Yeast infection in pregnancy? Think twice (...) about fluconazole. This study's findings regarding the risk of miscarriage may mean it's time to forego fluconazole in favor of topical azoles as first-line treatment. Practice changer: Avoid prescribing oral fluconazole in early pregnancy because it is associated with a higher rate of spontaneous abortion than is topical azole therapy. Stength of recommendation: B: Based on a large cohort study performed in Denmark. URI Part of Citation Journal of Family Practice, 65(9) 2016: 624-626 Rights

2017 PURLS

5. Fluconazole reduced the rate of recurrence of vulvovaginal candidiasis

Fluconazole reduced the rate of recurrence of vulvovaginal candidiasis Fluconazole reduced the rate of recurrence of vulvovaginal candidiasis | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Fluconazole reduced the rate of recurrence of vulvovaginal candidiasis Article Text Treatment Fluconazole reduced the rate of recurrence of vulvovaginal candidiasis Free Gene Harkless , RN, DNSc, ANRP Statistics from Altmetric.com Sobel JD, Wiesenfeld HC

Full Text available with Trip Pro

2006 Evidence-Based Nursing

6. Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis

Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 NHS Economic Evaluation Database.

7. Clinical effects of topical antifungal therapy in chronic rhinosinusitis: a randomized, double-blind, placebo-controlled trial of intranasal fluconazole. (PubMed)

Clinical effects of topical antifungal therapy in chronic rhinosinusitis: a randomized, double-blind, placebo-controlled trial of intranasal fluconazole. Several studies have been in favor of fungi as a possible pathogenesis of chronic rhinosinusitis (CRS); however, to date, there is no scientific consensus about the use of antifungal agents in disease management. The aim of the present study was to investigate the efficacy of intranasal fluconazole in improving disease symptoms and objective (...) outcomes of patients with CRS. A randomized, double-blind, placebo-controlled study was conducted on 54 patients who were diagnosed with CRS and had not been responsive to routine medical treatments. They were randomly assigned to receive either fluconazole nasal drop 0.2 % or placebo in addition to the standard regimen for a duration of 8 weeks. Patients' outcomes were evaluated according to Sino-Nasal Outcome Test 20 (SNOT-20), endoscopic scores, and Computed Tomography (CT) scores. No statistically

Full Text available with Trip Pro

2016 EXCLI journal

8. Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: a systematic review and meta-analysis of randomised controlled trials

Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: a systematic review and meta-analysis of randomised controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

9. Fluconazole

Fluconazole USE OF FLUCONAZOLE IN PREGNANCY 0344 892 0909 USE OF FLUCONAZOLE IN PREGNANCY (Date of issue: May 2016 , Version: 2.2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Fluconazole is a triazole antifungal commonly used in the treatment (...) of candidiasis. Standard fluconazole therapy generally comprises a single 150mg oral dose. Fluconazole is not recommended for use during pregnancy. However, vaginal candidiasis is common in pregnancy, and as fluconazole is sometimes prescribed to treat candidiasis that has not responded to topical clotrimazole treatment, exposure during pregnancy is not uncommon. Where fluconazole use is considered necessary in pregnancy, the risks and benefits of treatment should be discussed with the patient to support

2014 UK Teratology Information Service

10. Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis

Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis Neoh CF, Liew D, Slavin M, Marriott D, Chen SC, Morrissey O, Stewart K, Kong DC Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to determine the cost-effectiveness of anidulafungin versus fluconazole in the treatment of invasive candidiasis. The authors concluded that anidulafungin was cost-effective. The methods were adequate, and they and the results were sufficiently reported. Given the scope

Full Text available with Trip Pro

2011 NHS Economic Evaluation Database.

11. Recurrent tinea versicolor: treatment with itraconazole or fluconazole?

Recurrent tinea versicolor: treatment with itraconazole or fluconazole? BestBets: Recurrent tinea versicolor: treatment with itraconazole or fluconazole? Recurrent tinea versicolor: treatment with itraconazole or fluconazole? Report By: Anastasia Pantazidou, Marc Tebruegge - Senior House Officer, Department of Paediatrics, Specialist Registrar, Department of Paediatric Infectious Diseases respectively Search checked by Bob Phillips - Section Editor, Archimedes, Archives of Disease in Childhood (...) Institution: North Middlesex Hospital, London and St Mary's Hospital, London, UK Date Submitted: 26th October 2007 Date Completed: 26th October 2007 Last Modified: 26th October 2007 Status: Green (complete) Three Part Question In [a child/adolescent with tinea versicolor] is [oral itraconazole more effective than oral fluconazole] as [regards cure]? Clinical Scenario A 14-year-old girl is seen in the paediatric outpatient department. She was referred by her general practitioner (GP) with persistent tinea

2007 BestBETS

12. Can oral fluconazole be used with breastfeeding?

Can oral fluconazole be used with breastfeeding? Can oral fluconazole be used with breastfeeding? – SPS - Specialist Pharmacy Service – The first stop for professional medicines advice Menu · · Published 21st February 2017 , updated 28th November 2018 There are very limited data on the excretion of fluconazole in breast milk. Fluconazole, after a 200 mg oral dose, produces levels in breast milk similar to those found in maternal plasma. Fluconazole is recommended for use in the treatment (...) of neonates with fungal infections at a dose starting at 3 mg/kg every 72 hours. The calculated dose of fluconazole ingested by an infant feeding at times of peak milk levels of fluconazole would be approximately 0.6 mg/kg/day, which is 60% of the neonatal dose and 20% of the dose for infants aged one month and over. Fluconazole is often used to treat lactation-associated candidal infections, and has been used to treat serious candidal infections in preterm and full term neonates. There is therefore

2017 Specialist Pharmacy Services

13. Miconazole nitrate vaginal suppository 1,200 mg versus oral fluconazole 150 mg in treating severe vulvovaginal candidiasis. (PubMed)

Miconazole nitrate vaginal suppository 1,200 mg versus oral fluconazole 150 mg in treating severe vulvovaginal candidiasis. Miconazole is a synthetic imidazole antifungal that has a broad spectrum of activity against Candida albicans and non-albicans Candida species. The aim of this study was to evaluate the efficacy and safety of miconazole nitrate vaginal suppository and oral fluconazole in treating severe vulvovaginal candidiasis (SVVC).In this prospective, randomized case control study, 577 (...) cases of consecutive patients with SVVC were studied at the Gynecological Clinic of Peking University Shenzhen Hospital from January 1, 2009 through December 31, 2010. Patients with SVVC were treated with two doses of miconazole nitrate vaginal suppository 1,200 mg or two doses of fluconazole 150 mg. The patients were followed up for 7-14 and 30-35 days following the second dose of therapy.The mycological cure rates of the patients on days 7-14 of follow-up were 75.9% (220/290) and 84.0% (241/287

Full Text available with Trip Pro

2015 Gynecologic and obstetric investigation

14. Proanthocyanidin polymeric tannins from Stryphnodendron adstringens are effective against fluconazole-resistant Candida spp. and treat vaginal candidiasis. (PubMed)

Proanthocyanidin polymeric tannins from Stryphnodendron adstringens are effective against fluconazole-resistant Candida spp. and treat vaginal candidiasis. The stem bark of Stryphnodendron adstringens (Mart.) Coville is popularly used as anti-inflammatory, astringent and in the treatment of wounds and vaginal infections. Several pharmacological activities have been scientifically proven by in vitro and in vivo experimental assays for antibacterial, antiviral, antiprotozoan, anti-inflammatory (...) and antioxidant.We investigated whether proanthocyanidin polymeric tannins from the Stryphnodendron adstringens stem bark with antifungal activity against Candida albicans in vitro are also active against planktonic and biofilm cells of Candida non-albicans (CNA, including fluconazole-resistant isolates) and are capable of controlling Candida vaginitis in vivo.A total of 46 clinical isolates and 5 reference Candida spp. strains were used in this study. The antifungal effects in vitro of tannins (F2 and sub

2018 Journal of Ethnopharmacology

15. Comparison of the therapeutic effects of Garcin(®) and fluconazole on Candida vaginitis. (PubMed)

Comparison of the therapeutic effects of Garcin(®) and fluconazole on Candida vaginitis. This study aimed to determine and compare the effects of garlic tablets (Garcin(®)) and fluconazole on Candida vaginitis in women who presented to a health centre in Koohdasht, Iran, from August 2011 to March 2012.The clinical trial was conducted on 110 married women (aged 18-44 years) who had complaints of itching or a burning sensation in the vaginal area. Candida vaginitis was diagnosed by pH measurement (...) of vaginal secretions, direct microscopic evaluation and Sabouraud dextrose agar cultures of the vaginal discharge. On confirmation of diagnosis, the patients were randomly divided into two groups (n = 55). One group received 1,500 mg of Garcin tablets daily and the other received fluconazole tablets 150 mg daily, over a period of seven days. Four to seven days after the completion of treatment, patients were examined for treatment response and possible side effects.Complaints related to the disease

Full Text available with Trip Pro

2015 Singapore medical journal

16. Comparative clinical trial: fluconazole alone or associated with topical ketoconazole in the treatment of pityriasis versicolor. (PubMed)

Comparative clinical trial: fluconazole alone or associated with topical ketoconazole in the treatment of pityriasis versicolor. The efficacy of ketoconazole and fluconazole in pityriasis versicolor had been proved.To compare the efficacy and the safety of two doses of fluconazole given 1 week apart alone or associated to ketoconazole shampoo.Our study included all patients with pityriasis versicolor who attended in dermatology department of Habib Thameur Hospital, Tunis (over a 21-month period (...) ). During the considered period, patients were randomly assigned in two study groups: G1 receiving fluconazole two doses 300mg given 1 week apart with G2 taken an association of fluconazole (two doses 300mg given 1 week apart) and ketoconazole shampoo the first day.Seventy one patients were enrolled in our study: 35 in the fluconazole group and 36 in the fluconazole associated to ketoconazole shampoo comparator group. The mean age was 29.1 years [16-70 years].  Concerning the clinical form, 27% had

2016 La Tunisie médicale

17. [Clinical efficacy of fluconazole, tinidazole and clindamycin vs fluconazole, tinidazole and azithromycin in the treatment of mixed cervical-vaginal infections, included those caused by Mycoplasma and Chlamydia trachomatis].

[Clinical efficacy of fluconazole, tinidazole and clindamycin vs fluconazole, tinidazole and azithromycin in the treatment of mixed cervical-vaginal infections, included those caused by Mycoplasma and Chlamydia trachomatis]. In the United States 19 million people acquire a sexually transmitted disease every year. Sexually transmitted diseases impact in gynecological terms because they may cause sterility, infertility and ectopic pregnancy.To compare the effectiveness of two combinations (...) of three oral antimicrobial drugs in the treatment of mixed cervical-vaginal infections, included those caused by Mycoplasma and Chlamydia trachomatis.Aclinical, random, comparative, double-blind study included 50 patients assisting to infectology consult with diagnosis of mixed cervical-vaginal infection. Patients were divided into two groups: Group A (n = 25): fluconazole 37.5 mg, tinidazole 500 mg and azithromycin 250 mg; group B (n = 25): fluconazole 37.5 mg, tinidazole 500 mg and clindamycin 312.5

2013 Ginecología y obstetricia de México

18. Oral fluconazole 150 mg single dose versus intra-vaginal clotrimazole treatment of acute vulvovaginal candidiasis. (PubMed)

Oral fluconazole 150 mg single dose versus intra-vaginal clotrimazole treatment of acute vulvovaginal candidiasis. To compare the safety and efficacy of fluconazole 150 mg single dose and intra-vaginal clotrimazole 200mg per day for six days in the treatment of the acute episode of vulvovaginal candidiasis (VVC).In a prospective study, 142 patients with acute clinical and mycological confirmed VVC were enrolled and divided randomly in two groups. 70 patients received intra-vaginal tablet (200mg (...) ) daily for seven days, whereas 72 patients received single dose oral fluconazole (150 mg). Second and third visits were done for all patients seven days and one month after treatment and the clinical and mycological outcomes evaluated. The analysis performed using SPSS statistical software (version 15).At the second visit, 61 patients (84.7%) were cured clinically (inflammation and discharge) and 58 patients (80.5%) mycologically in fluconazole group and 60 patients (83.3%) were cured clinically

Full Text available with Trip Pro

2011 Journal of infection and public health

19. Anidulafungin versus fluconazole for invasive candidiasis. (PubMed)

Anidulafungin versus fluconazole for invasive candidiasis. Anidulafungin, a new echinocandin, has potent activity against candida species. We compared anidulafungin with fluconazole in a randomized, double-blind, noninferiority trial of treatment for invasive candidiasis.Adults with invasive candidiasis were randomly assigned to receive either intravenous anidulafungin or intravenous fluconazole. All patients could receive oral fluconazole after 10 days of intravenous therapy. The primary (...) efficacy analysis assessed the global response (clinical and microbiologic) at the end of intravenous therapy in patients who had a positive baseline culture. Efficacy was also assessed at other time points.Eighty-nine percent of the 245 patients in the primary analysis had candidemia only. Candida albicans was isolated in 62% of the 245 patients. In vitro fluconazole resistance was infrequent. Most of the patients (97%) did not have neutropenia. At the end of intravenous therapy, treatment

2007 NEJM

20. Use of Oral Probiotics as an Adjunctive Therapy to Fluconazole in the Treatment of Yeast Vaginitis

Use of Oral Probiotics as an Adjunctive Therapy to Fluconazole in the Treatment of Yeast Vaginitis Use of Oral Probiotics as an Adjunctive Therapy to Fluconazole in the Treatment of Yeast Vaginitis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove (...) one or more studies before adding more. Use of Oral Probiotics as an Adjunctive Therapy to Fluconazole in the Treatment of Yeast Vaginitis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00479947 Recruitment Status : Unknown Verified May 2007 by Faith Mediplex. Recruitment status was: Recruiting

2007 Clinical Trials